Latest Updates

EBITDA margins reported at 17.5 per cent

Approval under the PEPFAR scheme, total PEPFAR approvals at 20

Ranexa tablets, 500 mg and 1000 mg had US sales of approximately $ 443.4 million

Consolidated Net Profit increased by 64.38 per cent to Rs. 1286.76 million in Q1 FY13-14

PIL petitioners to submit suggestions in two weeks; ISCR expresses concerns on slowdown of trial approvals

Capitol Ingredients will be consolidated with staff from the IMCD Personal Care team and will run as a separate division of IMCD…

Receives a total cash consideration of Rs 1050 crores as a part of the transaction from Claris-Otsuka

Karnataka state regulators write to state govt; Maharashtra and Gujarat gears up for action

Generic Nuvigil tablets and Generic Oracea capsules to improve wakefulness in adult patients with excessive sleepiness associated…

Posts revenues at Rs 1480.5 million during the first quarter of FY 2013-14

Numerous activities were conducted in over 64 Indian cities and around 10million diabetics were reached out through this campaign

Bags award for excellence in public relations programming in the employee communications category

To allow use of Potelligent CHOK1SV Cell Line for therapeutic antibody research and development

Organises community-based awareness activities with support from Bristol Myers Squibb Foundation at slum areas in Mumbai

Focuses on European market and setting up of a new R&D centre in Ahmedabad

Alleges that the real problem is infrastructure not availability of doctors

The upgrade will give Piramal two commercial grade ADC suites at the Grangemouth facility

In Q2' 13, the company posts consolidated revenues of Rs 228 crores

Zydus & IDRI will collaborate to conduct clinical development activities in India for visceral leishmaniasis (Kala-Azar)